Stockhub

VioQuest Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

10 August 2022

  • curprev 21:4021:40, 10 August 2022‎ Paris talk contribs‎ 939 bytes +939‎ Created page with "VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/VioQuest_Pharmaceuticals,_Inc.’